Upregulation of long non-coding RNA LOC284454 may serve as a new serum biomarker for head and neck cancers

Chunmei Fan
    central south university

Jinpeng Wang
    central south university

Yanyan Tang
    central south university

Shanshan Zhang
    central south university

Fang Xiong
    central south university

Can Guo
    central south university

Yanhong Zhou
    central south university

Zheng Li
    central south university

Xiaoling Li
    central south university

Yong Li
    Baylor college of medicine

Guiyuan Li
    central south university

Zhaoyang Zeng
    central south university

Wei Xiong (✉️ xiongwei@csu.edu.cn)
    Central South University

Research article

Keywords: head and neck cancers, long noncoding RNAs, receiver operating characteristic, serum biomarker
Abstract

Background: Identification of effective diagnostic and prognostic biomarkers of cancer is necessary for improving precision medicine. Long non-coding RNAs (lncRNAs) play an important regulatory role in tumor initiation and progression. The lncRNA LOC284454 is distinctly expressed in various head and neck cancers (HNCs), as demonstrated by our previous bioinformatics analysis. However, the expression levels and functions of LOC284454 in cancer are still unclear.

Methods: We investigated the dysregulation of lncRNAs in HNCs using the GEO database and found that LOC284454 was highly expressed in HNCs. Serum samples from 212 patients with HNCs and 121 normal controls were included in this biomarker study. We measured the expression of LOC284454 in the sera of HNC patients and normal controls using RT-qPCR. Receiver operating characteristics (ROC) analysis is an important statistical method that is widely used in clinical diagnosis and disease screening. ROC was used to analyze the clinical value of LOC284454 in the early diagnosis of HNCs.

Results: LOC284454 was significantly upregulated in the sera of patients with nasopharyngeal carcinoma, oral cancer, and thyroid cancer. LOC284454 upregulation had good clinical diagnostic value in these cancers, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834, respectively.

Conclusions: LOC284454 may be a valuable serum biomarker for HNCs facilitating the early diagnosis of malignant cancers. Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs. This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.

Highlights

1. This is the first study examining LOC284454 expression in serum of HNCs patients.
2. This study provides the first evidence of LOC284454 as a serum biomarker for HNCs.

Background

Head and neck cancers (HNCs), including cancers of the oral cavity, tongue, hypopharynx, nasopharynx, larynx, and thyroid, are the sixth most common cancers worldwide, with an estimated incidence of more than 500,000 new cases each year^{15,49,52}{Argiris, 2008 #1105}{Argiris, 2008 #1105}. Most patients are in an advanced stage of HNCs at the time of diagnosis, with cervical lymph node involvement and/or distant metastasis. In these patients, the risk of metastasis and recurrence is significantly increased, and the mortality rate rises sharply.

Effective biomarkers for early diagnosis and prognosis are important for reducing the mortality of HNCs. Liquid biopsy is currently an effective and non-invasive method. Some serum markers, such as Epstein Barr virus DNA and microRNAs (miRNAs), lactate dehydrogenase, and antigens have been recognized for
their clinical value\textsuperscript{8, 10, 36, 38, 39, 42, 43, 48}. However, they also have some limitations. Identifying serum biomarkers with high sensitivity and specificity is an urgent goal.

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that do not encode proteins\textsuperscript{2, 17-19, 21, 53, 58}. In recent years, many studies have shown that a variety of lncRNAs are frequently expressed in malignant cancers and may participate in the initiation and development of malignant cancers\textsuperscript{9, 28, 30-32, 45, 51, 57}. For example, the AFAP1-AS1 lncRNA promotes the proliferation, migration, and invasion of cervical cancer, colon cancer and nasopharyngeal carcinoma (NPC) through different mechanisms\textsuperscript{3, 4, 29}. Additionally, PVT1 IncRNA induces radioresistance by regulating DNA repair and cell apoptosis, while promoting the proliferation of thyroid cancer through polycomb enhancer of zeste homolog 2/thyroid-stimulating hormone receptor\textsuperscript{23, 25, 47}. However, the functional importance of most lncRNAs has not yet been elucidated, including their roles in human tumors. Only a few lncRNAs have been reported to have clinical implications for early screening and prognosis.

Presently, we examined the expression level of LOC284454 in patients’ serum with HNCs and evaluated its clinical significance as a serum biomarker for early diagnosis.

**Methods**

**Serum collection**

We used blood collection tubes containing anticoagulants, mixed gently after blood collection. The samples were centrifuged at 1000-3000 rpm for 10 minutes, the supernatant was collected for RNA extraction. Blood samples were transported on ice and stored in \(-80^\circ\text{C}\) refrigerator. Discard the hemolysis and hyperlipidemia samples. The patients had not received any radio-chemotherapy or surgery before diagnosis. In total, 333 serum samples were collected from Affiliated Cancer Hospital of Central South University within 2017. The samples were collected from 121 normal donors randomly and 212 HNC patients. Of the 212 HNC serum, 100 were NPC, 55 were oral cancer, and 57 were thyroid cancer serum samples. Clinical data of patients is available in supplementary table 1&2, except for 30 cases of NPC patients are not available. This study was approved by the Ethical Committee of Central South University. Written informed consent was obtained from all patients and healthy donors.

**RNA extraction and RT-qPCR**

Serum RNA was extracted using miRNeasy Serum/Plasma Kit (Qiagen, Germany). Since our common use housekeeping genes may change its expression in tumor serum, thus we introduced an external reference, pGL3\textsuperscript{5}. The pGL3 (1 ng, approximately \(2\times10^8\) copies) was added to serum samples according to the manufacturer’s protocol using an miRNeasy Serum/Plasma Kit (Qiagen, Germany). The extracted serum RNA was reverse transcribed using a Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA). Forward (F) and reverse (R) primers were synthesized by TSINGKE Biological Technology Company (China), as follows: \textit{LOC284454-F}, 5′-ATTACAGGTGGCTCAGGTGT-3′, \textit{LOC284454-R}, 5′-
CTTCAGTGTGCCTCCTCAGT-3′; and pGL3-F, 5′-TCCATCTTGCTCAAACCCC-3′, pGL3-R, 5′-TCGTCTTTTCTTGCTCAAACCC-3′. The probe sequences were as follows: LOC284454-P, 5′-FAM-CGTGCCTGTCTTTTCTCCACTATCTTG-BHQ1-3′ and pGL3-P, 5′-HEX-ACGCAGGTGTCGCCAGGCTTCC-BHQ1-3′. Conventional SYBR-qPCR was performed using iTaq universal SYBR Green Supermix (Bio-Rad, USA). TaqMan-qPCR was performed using iTaq Universal Probes Supermix (Bio-Rad, USA). All RT-qPCR procedures were performed using a Bio-Rad CFX96 Multicolor Real-time PCR Detection System. TaqMan-qPCR allowed the simultaneous detection of two probes in the same tube (Bio-Rad, USA).

Statistical analysis

GSE61218 is from our group, which aims to identify significantly expressed lncRNAs in NPC tissues. GSE68799 is a RNA-Seq data identified human transcriptome alterations in NPC. RNA-Seq has been proved a tool with high throughput and coverage, reliable accuracy. GSE53819 is a genome-wide expressing profiling of NPC included 18 NPC tissue samples versus 18 control samples. They are paired tumor tissues and non-cancerous controls, which we thought can reduce individual heterogeneity. After discovering that LOC284454 is highly expressed in NPC, we also wanted to know whether it is highly expressed in other head and neck cancers, so we randomly selected the GEO dataset of oral cancer (GSE30784) and thyroid cancer (GSE33630). Data were analyzed using SPSS 13.0 (SPSS Inc., USA) and GraphPad 5.0 (GraphPad, USA). Student's t-tests were used to evaluate differences between two groups of samples. P-values< 0.05 were considered statistically significant. All the results obtained were from three independent replicates. The area under the curve (AUC), sensitivity, and specificity were obtained by receiver operating characteristic (ROC) curve analysis.

Results

LOC284454 is upregulated in NPC, oral cancer, and thyroid cancer

We explored the dysregulation of lncRNAs in HNCs using the GEO database. LOC284454 was significantly upregulated in several cancers, including NPC, oral cancer, and thyroid cancer. In our previous article, we performed gene expression profiling enrolled six inflammatory normal controls and 10 NPC tissues to identify differentially expressed lncRNAs (accession number GSE61218). 46506 lncRNA probes were included. The data showed that totally 1276 lncRNAs were differentially expressed, including 405 upregulated and 871 downregulated lncRNAs in NPC tissues. We selected top 20 highly expressed lncRNAs to validate. LOC284454 was one of the most significant and had not been detected its application as a serum biomarker (heatmap showed in Figure 1A) 11. In NPC, we integrated three sets of gene expression profiles, including GSE53819, GSE68799, GSE61218, which further demonstrated that LOC284454 is highly expressed in NPC. GSE30784 and GSE33630 were used to analyze oral cancer and thyroid cancer, respectively. The expression levels of LOC284454 were significantly higher in NPC (Figure 1a, P<0.001), oral cancer(Figure 1b, P<0.001), and thyroid cancer (Figure1c, P<0.001), compared to non-tumor tissues.
**LOC284454 expression is significantly increased in serum of patients with NPC**

SYBR-quantitative polymerase chain reaction (qPCR) was used to detect the expression of LOC284454 in the serum of 76 NPC patients and 51 healthy donors. LOC284454 expression level was significantly higher in the serum of patients with NPC (Figure 2a, \( P<0.001 \)).

Next, to eliminate systematic errors and make the results more reliable, we designed a TaqMan probe for LOC284454 and tested the same serum samples using TaqMan-qPCR. This examination also revealed significantly higher expression of LOC284454 in the serum of the NPC patients (Figure 2b, \( P<0.001 \)). This was consistent with previous conventional RT-qPCR results. Subsequent correlation analysis of the results obtained by SYBR-qPCR and TaqMan-qPCR demonstrated a good positive correlation between the two methods, which verified the reliability of this data (Figure 2c, \( P<0.001 \)).

We also verified the expression of LOC284454 in a larger cohort of 121 normal controls and 100 NPC patients (added some new samples to the original cohort). The expression of LOC284454 in the serum of NPC patients was significantly higher than that of the normal control group (Figure 2d, \( P<0.001 \)). Taken together, these results suggested that LOC284454 may be a potential serum marker for NPC.

**LOC284454 is highly expressed in serum of patients with oral cancer and thyroid cancer**

The results of the GEO database results suggested that LOC284454 may be dysregulated in oral cancer and thyroid cancer. Therefore, we next detected the expression of LOC284454 in the serum of patients with these cancers using TaqMan-qPCR. LOC284454 was significantly upregulated in the serum of patients with oral cancer and thyroid cancer compared with those of the normal controls (Figure 3a & 3b, \( P<0.001 \)). Notably, a significant difference was evident in the proportion of men and women with thyroid cancer (43 females and 14 males). To exclude gender effects, we analyzed the expression of LOC284454 in 43 female thyroid cancer patients and 36 normal women. The expression of LOC284454 was higher in the tumor serum than in the normal group (Figure 3c, \( P=0.024 \)). The collective results demonstrated that the expression level of LOC284454 in the serum of patients with oral and thyroid cancers was significantly higher than normal controls.

**Diagnostic value of serum LOC284454 for HNC patients**

ROC is commonly used to assess the diagnostic value of biomarkers. AUC refers to the area enclosed by the curve and the 45-degree diagonal line, which is used to quantify the diagnostic value. An AUC value <0.5 indicates almost no diagnostic value. AUCs of 0.5~0.7, 0.7~0.9, and >0.9 indicate low, moderate, and high diagnostic value, respectively. Values exceeding 0.9 also indicate high specificity and sensitivity. When the sensitivity/(1-specificity) value is the largest, its corresponding row is the best cut-off point.

The AUC values of LOC284454 in NPC (Figure 4a), oral cancer (Figure 4b), and thyroid cancer (Figure 4c) were 0.931, 0.698, and 0.834, respectively, indicating that LOC284454 might be an appropriate diagnostic biomarkers for these cancers (Table 1). However, we analyzed the LOC284454 expression level as well as
of patients’ clinical characteristics and found that LOC284454 had no significant correlation with pathological stages, gender, and age distribution (Supplemental Table 1).

Table 1. ROC curves analysis of LOC284454 in nasopharyngeal carcinoma (NPC) 
oral cancer and thyroid cancer

| cancer types           | Area   | Std. Error | Asymptotic Sig. | Asymptotic 95% Confidence Interval | Sensitivity | Specificity |
|------------------------|--------|------------|-----------------|------------------------------------|-------------|-------------|
| nasopharyngeal carcinoma | 0.931  | 0.017      | 0.000           | Lower Bound: 0.899, Upper Bound: 0.964 | 0.770       | 0.959       |
| oral cancer            | 0.698  | 0.047      | 0.000           | Lower Bound: 0.606, Upper Bound: 0.791 | 0.582       | 0.810       |
| thyroid cancer         | 0.834  | 0.032      | 0.000           | Lower Bound: 0.771, Upper Bound: 0.898 | 0.877       | 0.620       |

a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5

Discussion

HNCs rank as the sixth most common type of cancers worldwide. The cancers are often at an advanced stage at the time of diagnosis and display frequent recurrence and metastasis. Thus, prognosis and patient survival are poor. Radiotherapy and chemotherapy have largely improved the treatment of HNCs in recent decades. However, the 5-year survival rate is still very low. Improving the accuracy of early diagnosis could significantly improve the disease-free survival rate of patients.

Compared with other detection methods, liquid biopsy has become the preferred choice for disease screening because of its non-invasiveness, low cost, ease of use, and high stability. Some biomarkers for HNCs, including proteins, miRNAs, and EBV DNA, have been identified using liquid biopsies. However, each of these markers has its own disadvantages, including low positive rates, high false positive rate, need for experienced operators, and instrumental limitations. Therefore, finding effective early diagnostic markers in serum is critical for the treatment of HNCs.

LncRNAs have been reported to participate in the pathogenesis of HNCs. LncRNAs circulating in the serum or other bodily fluids present promising biomarkers for clinical diagnostic and prognostic applications. For example, serum MALAT1, AFAP1-AS1, and AL359062 can function as diagnostic and prognostic biomarkers for NPC. Notably, the upregulation of the ATB lncRNA can accurately predict papillary thyroid carcinoma and its prognosis. However, few studies have examined novel LncRNAs expression in serum in HNCs.

The LOC284454 lncRNA is located on 19p13.12 and the miR-23-a~27a~24-2 cluster is present upstream of the same transcript. LOC284454 is a nuclear localized and chromatin associated lncRNA. LOC284454 RNA is found only in primates and is highly conserved. In our previous study, we demonstrated that LOC284454 promotes migration and invasion of NPC cells in vitro and in vivo, and is associated with skeletal remodeling and adhesion signal pathways. In this study, based on the feasibility of SYBR-qPCR
and TaqMan-qPCR tests of serum \( \text{LOC284454} \), we found that compared with healthy controls, the expression of \( \text{LOC284454} \) was higher in NPC, oral cancer, and thyroid cancer, indicating that \( \text{LOC284454} \) might be very important for the diagnosis of HNCs. To confirm this, we used ROC curve analysis to evaluate the diagnostic value of \( \text{LOC284454} \). The AUC values of \( \text{LOC284454} \) in NPC, oral cancer, and thyroid cancer were 0.931, 0.698, and 0.834, respectively, indicating that \( \text{LOC284454} \) might be an appropriate diagnostic biomarker for these cancers. Even though we found that \( \text{LOC284454} \) is highly expressed in NPC, oral cancer, and thyroid cancer, that does not mean \( \text{LOC284454} \) can be generalized to all cancers. Study have shown that \( \text{LOC284454} \) is significantly reduced in prostate, uterus, breast, and kidney cancer\(^7\), suggesting that \( \text{LOC284454} \) is specifically highly expressed in HNC.

Real-time PCR can sensitively detect small changes in nucleic acids based on fluorescent dyes and fluorescently labeled probes. In TaqMan-PCR, a fluorescent reporter group and a fluorescence quenching group are labeled on both ends of the probe\(^1,14,16,55\). When amplified, the 5'-3' exonuclease activity of the Taq enzyme degrades the probe. The fluorescent reporter group and the fluorescence quenching group are separated, so that the fluorescence monitoring system can receive the fluorescent signal, and the accumulation of fluorescent signal is completely synchronized with the formation of the PCR product\(^20,24,37\). Since the qPCR instrument has a multicolor fluorescent channel, the experimental group and the control group are allowed to react in the same tube with the same cDNA template, which can reduce systematic errors and improve the specificity and sensitivity of the experiment\(^40\). This is also one of the highlights of this study and might be very useful for future detection of biomarkers.

We found that \( \text{LOC284454} \) is highly expressed in the peripheral blood of HNCs. Why it remains stable in the peripheral blood is still unclear. We suspect that this may be related to exosomes or vesicles. Exosomes can encapsulate proteins, lipids, and nucleic acids, remain stable in the tumor microenvironment, and are important in tumor metastasis\(^46\). Recent studies have shown that non-coding RNAs exist in exosomes. Exosomes can carry non-coding RNAs to non-adjacent cells for information communication and can participate in tumor development\(^26,27,35,44\). More research is needed to elucidate these mechanisms.

In summary, our results verified that \( \text{LOC284454} \) is significantly upregulated in the serum of patients with NPC, oral cancer, and thyroid cancer based on SYBR-qPCR and TaqMan-qPCR. Moreover, ROC curve data indicate that \( \text{LOC284454} \) could be used as a novel diagnostic biomarker for HNCs. Further research should focus on follow-up investigations to study the prognostic value of \( \text{LOC284454} \). It is hoped that the development of new technologies, such as digital PCR, will make it easier to detect phenotypic specific molecular changes, and will increase the sensitivity and specificity of biomarkers.

**Conclusions**

In this study, we investigated the dysregulation of IncRNAs in HNCs using the GEO database and found that \( \text{LOC284454} \) was highly expressed in HNCs (nasopharyngeal carcinoma, oral cancer, and thyroid cancer). We measured the expression of \( \text{LOC284454} \) in the serum of HNC patients via Taqman RT-qPCR.
We then used ROC curve to analyze the clinical value of LOC284454 in the early diagnosis of HNCs. LOC284454 upregulation had good clinical diagnostic value in nasopharyngeal carcinoma, oral cancer, and thyroid cancer, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834, respectively. LOC284454 may be a valuable serum biomarker for HNCs facilitating the early diagnosis of malignant cancers. Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs. This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.

Abbreviations

LncRNAs: Long non-coding RNAs; HNCs: Head and neck cancers; ROC: Receiver operating characteristics; miRNA: microRNA; NPC: Nasopharyngeal carcinoma; AUC: The area under the curve

Declarations

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Central South University and in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all patients and healthy donors.

Consent to publish

Each author of this article has read the manuscript and agreed to publish.

Availability of data and material

The authors declared that all the data were available on line or from the corresponding author on reasonable request.

Competing interests

There are no potential conflicts of interest.

Acknowledgment

Not applicable.

Funding

This work has been supported by the National Natural Science Foundation of China (81672683, 81702907, 81772928, 81872278, 81803025 and 81972776), the Natural Science Foundation of Hunan Province (2017SK21005, 2018JJ3704, 2018JJ3815, 2018SK21210, 2018SK21211), the 111 Project (111-
2-12). Graduate students independently explore innovative projects (2019zzts089), Special Scholarship for Study Abroad of Central South University.

Authors’ contributions

WX and ZYZ designed and revised the manuscript. CMF, JPW and YYT wrote the manuscript and drew figures. SZ, FX, CG, YHZ, ZL, XLL, YL and GYL participated in the design of the manuscript. All the authors read and approved the final version of the manuscript.

References

1 Androvic P, Valihrach L, Elling J, et al. Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification. Nucleic acids research 2017; 45: e144. 2 Bo H, Gong Z, Zhang W, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget 2015; 6: 20404-20418. 3 Bo H, Fan L, Li J, et al. High Expression of IncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis. J Cancer 2018; 9: 4677-4683. 4 Bo H, Fan L, Gong Z, et al. Upregulation and hypomethylation of IncRNA AFAP1AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. Oncology reports 2019. 5 Crowley ST, Poliskey JA, Baumhover NJ, et al. Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver. Gene Ther 2015; 22: 993-999. 6 Cui M, Chang Y, Du W, et al. Upregulation of IncRNA-ATB by Transforming Growth Factor beta1 (TGF-beta1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells. Medical science monitor : international medical journal of experimental and clinical research 2018; 24: 5152-5158. 7 Das M, Renganathan A, Dighe SN, et al. DDX5/p68 associated IncRNA LOC284454 is differentially expressed in human cancers and modulates gene expression. RNA biology 2018; 15: 214-230. 8 Deng X, Xiong F, Li X, et al. Application of atomic force microscopy in cancer research. J Nanobiotechnology 2018; 16: 102. 9 Fan C, Tang Y, Wang J, et al. Role of long non-coding RNAs in glucose metabolism in cancer. Molecular cancer 2017; 16: 130. 10 Fan C, Tang Y, Wang J, et al. The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma. J Cancer 2018; 9: 2852-2864. 11 Fan C, Tang Y, Wang J, et al. Long non-coding RNA LOC284454 promotes migration and invasion of nasopharyngeal carcinoma via modulating the Rho/Rac signaling pathway. Carcinogenesis 2019; 40: 380-391. 12 Fan C, Tu C, Qi P, et al. GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma. J Cancer 2019; 10: 3926-3932. 13 Fan CM, Wang JP, Tang YY, et al. circMAN1A2 could serve as a novel serum biomarker for malignant tumors. Cancer science 2019; 110: 2180-2188. 14 Fernandes TJR, Costa J, Oliveira M, et al. Exploiting 16S rRNA gene for the detection and quantification of fish as a potential allergenic food: A comparison of two real-time PCR approaches. Food chemistry 2018; 245: 1034-1041. 15 Ge J, Wang J, Wang H, et al. The BRAF V600E mutation is a predictor of the effect of radiiodine therapy in papillary thyroid cancer. J Cancer 2020; 11: 932-939. 16 Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature biotechnology 2008; 26: 317-325. 17 Gong Z, Zhang S, Zhang W, et al. Long non-coding RNAs in cancer. Sci China Life Sci 2012; 55: 1120-1124. 18 Gong Z, Zhang S, Zeng Z, et al. LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and...
induces apoptosis in the nasopharyngeal carcinoma cell line HNE2. PloS one 2014; 9: e110674. 19 Gong Z, Yang Q, Zeng Z , et al. An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016; 37: 3683-3695. 20 Han Y, Hou SY, Ji SZ , et al. A novel method of multiple nucleic acid detection: Real-time RT-PCR coupled with probe-melting curve analysis. Analytical biochemistry 2017; 537: 50-55. 21 He B, Li W, Wu Y , et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103. Cell Death Dis 2016; 7: e2353. 22 He B, Zeng J, Chao W , et al. Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget 2017; 8: 41166-41177. 23 He Y, Jing Y, Wei F , et al. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. Cell Death Dis 2018; 9: 235. 24 Huangfu H, Xu W, Wang H , et al. Detection of Gallibacterium anatis by TaqMan fluorescent quantitative PCR. Avian pathology : journal of the WVPA 2018; 47: 245-252. 25 Jin K, Wang S, Zhang Y , et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. Cell Mol Life Sci 2019; 76: 4275-4289. 26 Karlsson O, Rodosthenous RS, Jara C , et al. Detection of long non-coding RNAs in human breastmilk extracellular vesicles: Implications for early child development. Epigenetics 2016: 0. 27 Kogure T, Yan IK, Lin WL , et al. Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. Genes & cancer 2013; 4: 261-272. 28 Li Q, Chen P, Zeng Z , et al. Yeast two-hybrid screening identified WDR77 as a novel interacting partner of TSC22D2. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016; 37: 12503-12512. 29 Lian Y, Xiong F, Yang L , et al. Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. Journal of experimental & clinical cancer research : CR 2018; 37: 253. 30 Liang F, Li Q, Li X , et al. TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer. International journal of oncology 2016; 49: 1046-1056. 31 Liao Q, Guo X, Li X , et al. Prohibitin is an important biomarker for nasopharyngeal carcinoma progression and prognosis. Eur J Cancer Prev 2013; 22: 68-76. 32 Liao Q, Zeng Z, Guo X , et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene 2014; 33: 2098-2109. 33 Mo Y, Wang Y, Xiong F , et al. Proteomic Analysis of the Molecular Mechanism of Lovastatin Inhibiting the Growth of Nasopharyngeal Carcinoma Cells. J Cancer 2019; 10: 2342-2349. 34 Mo Y, Wang Y, Zhang L , et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer 2019; 10: 3789-3797. 35 Pefanis E, Wang J, Rothschild G , et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell 2015; 161: 774-789. 36 Peng M, Mo Y, Wang Y , et al. Neoantigen vaccine: an emerging tumor immunotherapy. Molecular cancer 2019; 18: 128. 37 Qiu L, Chen MM, Wan XY , et al. Detection and quantification of shrimp hemocyte iridescent virus by TaqMan probe based real-time PCR. Journal of invertebrate pathology 2018; 154: 95-101. 38 Ren D, Hua Y, Yu B , et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular cancer 2020; 19: 19. 39 Song Y, Li X, Zeng Z , et al. Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1. Oncotarget 2016; 7:
36783-36799. 40 Su Y, Liu Y, Chen Y, et al. A novel duplex TaqMan probe-based real-time RT-qPCR for detecting and differentiating classical and variant porcine epidemic diarrhea viruses. Molecular and cellular probes 2018; 37: 6-11. 41 Tang L, Wei F, Wu Y, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. Journal of experimental & clinical cancer research : CR 2018; 37: 87. 42 Tu C, Zeng Z, Qi P, et al. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens. J Virol 2017; 91. 43 Tu C, Zeng Z, Qi P, et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole genome sequencing. Carcinogenesis 2018. 44 Wang D, Tang L, Wu Y, et al. Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci 2020. 45 Wang J, Shao N, Ding X, et al. Crosstalk between transforming growth factor-beta signaling pathway and long non-coding RNAs in cancer. Cancer letters 2016; 370: 296-301. 46 Wang JP, Tang YY, Fan CM, et al. The role of exosomal non-coding RNAs in cancer metastasis. Oncotarget 2018; 9: 12487-12502. 47 Wang W, Zhou R, Wu Y, et al. PVT1 Promotes Cancer Progression via MicroRNAs. Front Oncol 2019; 9: 609. 48 Wang YA, Li XL, Mo YZ, et al. Effects of tumor metabolic microenvironment on regulatory T cells. Molecular cancer 2018; 17: 168. 49 Wei F, Wu Y, Tang L, et al. Trend analysis of cancer incidence and mortality in China. Sci China Life Sci 2017; 60: 1271-1275. 50 Wei F, Tang L, He Y, et al. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell Death Dis 2018; 9: 432. 51 Wei F, Jing YZ, He Y, et al. Cloning and characterization of the putative AFAP1-AS1 promoter region. J Cancer 2019; 10: 1145-1153. 52 Wu C, Li M, Meng H, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci 2019. 53 Wu P, Mo Y, Peng M, et al. Emerging role of tumor-related functional peptides encoded by IncRNA and circRNA. Molecular cancer 2020; 19: 22. 54 Wu Y, Wei F, Tang L, et al. Herpesvirus acts with the cytoskeleton and promotes cancer progression. J Cancer 2019; 10: 2185-2193. 55 Xiao L, Wei F, Liang F, et al. TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing. Carcinogenesis 2019; 40: 819-827. 56 Xiong F, Deng S, Huang HB, et al. Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. Chin Med J (Engl) 2019; 132: 749-752. 57 Zhang W, Huang C, Gong Z, et al. Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. J Mol Histol 2013; 44: 545-554. 58 Zhou Y, Liao Q, Li X, et al. HYOU1, Regulated by LPLUNC1, Is Up-Regulated in Nasopharyngeal Carcinoma and Associated with Poor Prognosis. J Cancer 2016; 7: 367-376.

Figures
Figure 1

Upregulation of LOC284454 in head and neck cancers in the GEO database. LOC284454 was significantly upregulated in several head and neck cancers, including nasopharyngeal carcinoma(a), oral cancer(b), and thyroid cancer(c).
Figure 2

LOC284454 expression is significantly higher in sera of patients with NPC. (a). SYBRGreen quantitative polymerase chain reaction (qPCR) assay was used to detect the expression of LOC284454 in the sera of...
76 NPC patients and 51 healthy donors. (b). A TaqMan probe for LOC284454 was used to detect the expression of LOC284454 in the same samples. (c). Correlation analysis of the results obtained by SYBR-qPCR and TaqMan-qPCR. (d). Verification of the expression of LOC284454 in 100 NPC and 121 normal control samples.
LOC284454 is highly expressed in sera of patients with oral cancer and thyroid cancer. TaqMan-qPCR to detect the expression of LOC284454 in oral cancer (a) and thyroid cancer (b). (c). Expression of
LOC284454 in 43 female thyroid cancer patients and 36 normal women.
Figure 4

(a) NPC

Sensitivity vs. 1-Specificity

AUC = 0.931

(b) Oral carcinoma

Sensitivity vs. 1-Specificity

AUC = 0.698

(c) Thyroid carcinoma

Sensitivity vs. 1-Specificity

AUC = 0.834
Diagnostic value of serum LOC284454 for HNC patients ROC analysis was performed to evaluate the diagnostic value of LOC284454. The AUC values of LOC284454 in NPC(a), oral cancer(b), and thyroid cancer(c) were 0.931, 0.698, and 0.834, respectively.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaltable1.Genderandagedistribution.docx
- Supplementarytable2.Clinicaldata.xlsx